Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Sales: 2021-2025

Historic Return on Sales for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to 681.11%.

  • SAB Biotherapeutics' Return on Sales rose 71288.00% to 681.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 681.11%, marking a year-over-year increase of 71288.00%. This contributed to the annual value of -31.72% for FY2024, which is 1287.00% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Return on Sales stood at 681.11%, which was up 62.13% from 420.11% recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Return on Sales peaked at 681.11% during Q3 2025, and registered a low of -166.82% during Q1 2025.
  • Over the past 3 years, SAB Biotherapeutics' median Return on Sales value was -14.50% (recorded in 2024), while the average stood at 74.04%.
  • Examining YoY changes over the last 5 years, SAB Biotherapeutics' Return on Sales showed a top increase of 71,288bps in 2025 and a maximum decrease of 15,150bps in 2025.
  • SAB Biotherapeutics' Return on Sales (Quarterly) stood at -0.28% in 2021, then tumbled by 50bps to -0.78% in 2022, then slumped by 1,806bps to -18.85% in 2023, then plummeted by 740bps to -26.24% in 2024, then spiked by 71,288bps to 681.11% in 2025.
  • Its Return on Sales was 681.11% in Q3 2025, compared to 420.11% in Q2 2025 and -166.82% in Q1 2025.